Skip to main content
. 2022 Jul 21;6(5):399–408. doi: 10.1016/j.mayocpiqo.2022.07.001

Table 4.

Comparison of 2 Groups Defined by the 24 mm Pulmonary Artery Diameter Cutoff

. PA<24.5 mm PA≥24.5 mm Test P value
Age 62±17 65±16 t .112
Female gender 51 (36.4%) 99 (30.5%) Chi2 .234
Blood type
 O 42 (30%) 110 (33.8%) Chi2 .367
 A 61 (43.6%) 113 (34.8%)
 B 11 (7.9%) 40 (12.3%)
 AB 7 (5%) 15 (4.6%)
 UNK 19 (13.6%) 47 (14.5%)
Negative Rhesus antigen 12 (9.9%) 25 (9%) Chi2 .851
Direct admission to ICU 10 (7.1%) 38 (11.7%) Chi2 .183
Weight 76±14 83±17 t <.001
Hypertension 70 (50%) 194 (59.7%) Chi2 .066
Diabetes mellitus 34 (24.3%) 101 (31.1%) Chi2 .149
Immunosuppression 13 (9.3%) 34 (10.5%) Chi2 .741
Cardiovascular disease 30 (21.4%) 94 (28.9%) Chi2 .109
Chronic renal failure 8 (5.7%) 66 (20.3%) Chi2 <.001
Lung Disease 28 (20.6%) 65 (20.5%) Chi2 .999
Smoker 30 (22.1%) 84 (26.5%) Chi2 .346
Ground glass opacities (%) 21±16 27±19 t <.001
Lobar condensation 9 (6.4%) 29 (8.9%) Chi2 .462
Pulmonary embolism 0 (0%) 3 (0.9%) F .557
Leucocytes 6850 (5200-10,450) 7100 (5200-10,000) MWU .904
Neutrophiles 5165 (3625-7965) 5430 (3590-8050) MWU .746
Lymphocytes 870 (565-1280) 810 (540-1210) MWU .295
Ferritin 774 (456-1321) 732 (350.5-1328.5) MWU .682
LDH 318 (249-432) 336 (252-438) MWU .459
D-dimers 0.77 (0.44-2.1) 0.88 (0.48-1.67) MWU .61
CRP 76 (27-156) 94 (41.9-149) MWU .104
Procalcitonin 0.17 (0.07-0.33) 0.18 (0.09-0.48) MWU .193
HDL 1.13099 (0.86-1.42) 1.17 (0.99-1.34) MWU .715
LDL 3.17 (2.21-3.56868) 2.79 (2.07-3.46) MWU .236
Triglycerides 1.78 (1.25-2.46) 1.78 (1.34-2.48) MWU .469
Serum Creatinin 68.5 (54-90.5) 81 (65-116) MWU <.001
Oxygen (O2) needs at baseline
 No O2 46 (32.9%) 80 (24.6%) MWU .313
 O2 < 4 L/min 29 (20.7%) 92 (28.3%)
 O2 4-8 L/min 42 (30%) 93 (28.6%)
 Optiflow 23 (16.4%) 60 (18.5%)
NEWS2 score 5 (2-6) 5 (3-6) MWU .307
Length of stay 8.5 (5-14) 10 (6-18) MWU .028
ICU transfer 26 (18.6%) 84 (25.8%) Chi2 .097
Intubation 11 (7.9%) 59 (18.2%) Chi2 .004
Intubation day 8 (3-13) 6 (2-11) MWU .621
PCFS at discharge class 3-4 28 (23.0%) 75 (30.5%) Chi2 .140
PCFS at 2-Month class 3-4 6 (5.0%) 24 (9.8%) Chi2 .155

Chi2, Chi squared test; F, Fisher exact test; ICU, Intensive care unit; LDH, lactodehydrogenase; MWU, Mann-Whitney U test; PAD, pulmonary artery diameter; PCFS, Post–COVID-19 Functional Status scale; t, independent samples t test.Categorical data are presented as frequencies and percentages. Continuous data not departing from normality assumptions are presented as mean ± SD. Continuous data departing from normality assumptions are presented as median and its interquartile range.